“ We bio-engineer human skin in the laboratory ”
CUTISS , a Swiss med tech start-up has developed the world ’ s first machine to produce human skin grafts and a CE marked medical device for the treatment of skin pigmentation disorders . In an exclusive interaction , Dr Daniela Marino , CEO and co-founder , CUTISS shares details on the company ’ s focus on addressing skin pigmentation disorders , current activities , India plans and much more
BY RAHUL KOUL
Tell us briefly about your company ' s vision and journey so far ? What does the name CUTISS signify ?
Our focus is on skin , our physical barrier to protect us , and a key part of our identity . Our company name comes from the latin word cutis , meaning skin . We are a spin-off from the University of Zurich and the University Children ’ s Hospital in Zurich .
When our skin is damaged or affected by a disease , it has a huge impact not only on our physical health but also on our mental wellbeing . Think of a child who suffers severe burns in an accident , or a young adult who has
the autoimmune disorder Vitiligo .
Our vision is to provide patients with advanced skin cell and tissue therapy technology combining the scientific principles of biology , engineering , and deeptech :
DenovoSkin™ is a personalized , bioengineered dermo-epidermal skin graft that can be transplanted on burn or reconstructive wounds , promising a superior quality of life after surgery to millions of patients . Given its characteristics , the manufacturing of denovoSkin can be automated .
Viticell ® is a medical device that allows the repigmentation of discolored skin lesions using personalized cell therapy .
56
BioVoiceNews | March 2023